Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Aafke H. Honkoop"'
Autor:
Mette S. van Ramshorst, Aafke H. Honkoop, Vincent O. Dezentjé, Marie-Jeanne T. F. D. Vrancken Peeters, Caroline M.P.W. Mandigers, Sabine C. Linn, Agnes J. van de Wouw, Gabe S. Sonke, I.A.M. Mandjes, Erik van Werkhoven, Anna van der Voort, Jelle Wesseling, Inge Kemper, Laurence J. C. van Warmerdam, Lidwine W. Tick, Irma M. Oving
Publikováno v:
The Lancet Oncology. 19:1630-1640
Summary Background The optimal chemotherapy backbone for dual HER2 blockade in the neoadjuvant setting for early breast cancer is unknown. We investigated whether the addition of anthracyclines would improve pathological complete response compared wi
Autor:
Vivianne C. G. Tjan-Heijnen, Laurence J. C. van Warmerdam, Marta Lopez-Yurda, Edith van Druten, Hiltje de Graaf, Anouk K. M. Claessens, Aafke H. Honkoop, Maurice J.C. van der Sangen, Monique E. M. M. Bos, Jeanette M. Bouma, Jeany M. Rademaker-Lakhai, Frans L. G. Erdkamp
Publikováno v:
Breast Cancer Research and Treatment, 172(2), 413-423. Springer New York
Breast Cancer Research and Treatment, 172(2), 413-423. Springer, Cham
Breast Cancer Research and Treatment, 172(2), 413-423. Springer, Cham
PurposeWe determined if intermittent first-line treatment with paclitaxel plus bevacizumab was not inferior to continuous treatment in patients with HER2-negative, advanced breast cancer.MethodsPatients were randomized to 2x4 cycles or continuous 8 c
Autor:
Anouk K. M. Claessens, Jeany M. Rademaker-Lakhai, Aafke H. Honkoop, Marta Lopez-Yurda, Vivianne C. G. Tjan-Heijnen, Frans L. G. Erdkamp, Hiltje de Graaf, Monique E. M. M. Bos, Jeanette M. Bouma
Publikováno v:
Acta Oncologica, 59(6), 713-722. Informa Healthcare
Acta Oncologica, 59(6), 713-722. Routledge/Taylor & Francis Group
Acta Oncologica, 59(6), 713-722. Routledge/Taylor & Francis Group
Background: Previously, we showed that reintroduction of the same (first-line) chemotherapy at progression could only partially make up for the loss in efficacy as compared to continuously delivered first-line chemotherapy. Here, we report the probab
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::68252ff0682fa6aee566b737eaa479a1
https://pure.eur.nl/en/publications/4999cf0a-42b3-4873-a80a-1840106c0e50
https://pure.eur.nl/en/publications/4999cf0a-42b3-4873-a80a-1840106c0e50
Autor:
Aafke H. Honkoop, Marie-Jeanne T. F. D. Vrancken Peeters, I.A.M. Mandjes, Caroline M.P.W. Mandigers, Irma M. Oving, Annelie J. Vulink, Lidwine W. Tick, Anna van der Voort, Inge Kemper, GS Sonke, Sabine C. Linn, Agnes J. van de Wouw, Mette S. van Ramshorst, Laurence J. C. van Warmerdam, Erik van Werkhoven, Jelle Wesseling
Publikováno v:
JAMA Oncology. 7:978
Importance Primary analysis of the TRAIN-2 study showed high pathologic complete response rates after neoadjuvant chemotherapy with or without anthracyclines plus dualERBB2(formerlyHER2) blockade. Objective To evaluate 3-year event-free survival (EFS
Autor:
Sabine C. Linn, Gabe S. Sonke, I.A.M. Mandjes, Inge Kemper, Carolien H. Smorenburg, Aafke H. Honkoop, Erik van Werkhoven, Jacqueline M. Stouthard, Irma M. Oving, Mette S. van Ramshorst, Vincent O. Dezentjé
Publikováno v:
The Breast. 29:153-159
Background The addition of pertuzumab to neoadjuvant trastuzumab-based chemotherapy improves pathologic complete response rates in HER2-positive breast cancer. However, increased toxicity has been reported with the addition of pertuzumab, and this ma
Autor:
Monique Hanse, Maurice de Wit, Ya Gao, Walter Taal, Jan Buter, Youri Hoogstrate, Peter A. E. Sillevis Smitt, Martin J. van den Bent, Annemiek M E Walenkamp, Johan M. Kros, Laurens V. Beerepoot, Bronno van der Holt, Hina Naz-Khan, Aafke H. Honkoop, Andrew P. Stubbs, René Böttcher, René M. Vernhout, Peter J. van der Spek, HM Oosterkamp, Lale Erdem-Eraslan, Pim J. French
Publikováno v:
Cancer Research, 76(3), 525-534. AMER ASSOC CANCER RESEARCH
Cancer Research, 76(3), 525-34. American Association for Cancer Research Inc.
Erdem-Eraslan, L, van den Bent, M J, Hoogstrate, Y, Naz-Khan, H, Stubbs, A, van der Spek, P, Böttcher, R, Gao, Y, de Wit, M, Taal, W, Oosterkamp, H M, Walenkamp, A, Beerepoot, L V, Hanse, M C J, Buter, J, Honkoop, A H, van der Holt, B, Vernhout, R M, Sillevis Smitt, P A E, Kros, J M & French, P J 2016, ' Identification of Patients with Recurrent Glioblastoma Who May Benefit from Combined Bevacizumab and CCNU Therapy : A Report from the BELOB Trial ', Cancer Research, vol. 76, no. 3, pp. 525-34 . https://doi.org/10.1158/0008-5472.CAN-15-0776
Cancer Research, 76(3), 525-534. American Association for Cancer Research Inc.
Cancer Research, 76(3), 525-34. American Association for Cancer Research Inc.
Erdem-Eraslan, L, van den Bent, M J, Hoogstrate, Y, Naz-Khan, H, Stubbs, A, van der Spek, P, Böttcher, R, Gao, Y, de Wit, M, Taal, W, Oosterkamp, H M, Walenkamp, A, Beerepoot, L V, Hanse, M C J, Buter, J, Honkoop, A H, van der Holt, B, Vernhout, R M, Sillevis Smitt, P A E, Kros, J M & French, P J 2016, ' Identification of Patients with Recurrent Glioblastoma Who May Benefit from Combined Bevacizumab and CCNU Therapy : A Report from the BELOB Trial ', Cancer Research, vol. 76, no. 3, pp. 525-34 . https://doi.org/10.1158/0008-5472.CAN-15-0776
Cancer Research, 76(3), 525-534. American Association for Cancer Research Inc.
The results from the randomized phase II BELOB trial provided evidence for a potential benefit of bevacizumab (beva), a humanized monoclonal antibody against circulating VEGF-A, when added to CCNU chemotherapy in patients with recurrent glioblastoma
Autor:
C.J. Rodenburg, Frans L. G. Erdkamp, J. Douma, Miriam Koopman, Aafke H. Honkoop, Gerard Vreugdenhil, J.M. Akkermans-Vogelaar, J. Wals, Ninja Antonini, C.J.A. Punt, R.S. de Jong
Publikováno v:
Annals of Oncology, 17, 10, pp. 1523-8
Annals of oncology, 17(10), 1523-1528. Oxford University Press
Annals of Oncology, 17, 1523-8
Annals of oncology, 17(10), 1523-1528. Oxford University Press
Annals of Oncology, 17, 1523-8
Contains fulltext : 50348.pdf (Publisher’s version ) (Closed access) BACKGROUND: Results on overall survival in randomised studies of mono- versus combination chemotherapy in advanced colorectal cancer patients may have been biased by an imbalance
Autor:
J. van den Bosch, S. de Groot, Judith R. Kroep, Jürgen Braun, Siu W. Lam, Epie Boven, Sabine C. Linn, Monique M.E.M. Bos, H. van Tinteren, Aafke H. Honkoop, Agnes Jager, A. J. Ten Tije
Publikováno v:
European Journal of Cancer, 50(18), 3077-3088. Pergamon
Lam, S W, de Groot, S M, Honkoop, A H, Jager, A, ten Tije, A J, Bos, M M E M, Linn, S C, Bosch, J, Kroep, J R, Braun, J J, van Tinteren, H & Boven, E 2014, ' Paclitaxel and bevacizumab with or without capecitabine as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: A multicentre, open-label, randomised phase 2 trial ', European Journal of Cancer, vol. 50, no. 18, pp. 3077-3088 . https://doi.org/10.1016/j.ejca.2014.10.008
European Journal of Cancer, 50(18), 3077-3088
European Journal of Cancer, 50(18), 3077-3088. Elsevier Ltd.
Lam, S W, de Groot, S M, Honkoop, A H, Jager, A, ten Tije, A J, Bos, M M E M, Linn, S C, Bosch, J, Kroep, J R, Braun, J J, van Tinteren, H & Boven, E 2014, ' Paclitaxel and bevacizumab with or without capecitabine as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: A multicentre, open-label, randomised phase 2 trial ', European Journal of Cancer, vol. 50, no. 18, pp. 3077-3088 . https://doi.org/10.1016/j.ejca.2014.10.008
European Journal of Cancer, 50(18), 3077-3088
European Journal of Cancer, 50(18), 3077-3088. Elsevier Ltd.
Background: The addition of bevacizumab to paclitaxel or capecitabine has demonstrated improved progression-free survival (PFS) and objective response rate (ORR) as compared with chemotherapy alone in patients with HER2-negative locally recurrent or
Autor:
G. Giaccone, Jorine H. Savonije, L.W. Wormhoudt, C.L. van Felius, C. J. van Groeningen, A. van Bochove, Aafke H. Honkoop
Publikováno v:
European journal of cancer (Oxford, England : 1990). 41(11)
This work was conducted to evaluate the effect of early intervention with epoetin alfa (EPO) on transfusion requirements, hemoglobin level (Hb), quality of life (QOL) and to explore a possible relationship between the use of EPO and survival, in pati